Scholarlink

<p>Resveratrol, a prominent member of the plant-derived stilbenoid family, exhibits diverse biological and pharmaceutical activities. Its methylated derivatives possess enhanced attributes compared to the parent compound, such as improved stability and bioavailability. Although resveratrol analogs are widely used in healthcare and industrial applications, their current production relies predominantly on plant extraction, which often leads to low yields and inconsistent product quality. Microbial biosynthesis offers a promising alternative to chemical synthesis and plant-based extraction. Furthermore, gene expression regulation of engineered microbes allows cells to respond to their environment and maintain proper cellular function, which results in improved target products. In this study, we developed synthetic gene clusters comprising <i>O</i>-methyltransferase from <i>Streptomyces avermitilis</i> (<i>SaOMT2</i>) and S-adenosylmethionine (SAM) synthase from <i>Escherichia coli</i> (<i>E. coli)</i> (<i>EcMetK</i>), resulting in the engineered <i>E. coli</i> biosynthesis of methylated resveratrol. The engineered C2 strain, in which both genes were individually regulated by T7 promoters and ribosome binding site (RBS), demonstrated a 6.1-fold increase in 4′-O-methylresveratrol production compared to the control strain C0 harboring SaOMT2. Optimization of culture conditions, including medium composition and substrate concentration, further enhanced bioconversion efficiency. The bioproductivity of 4′-O-methylresveratrol production was obtained as 476.72&#xa0;µM (~ 115.485&#xa0;mg/L) at 36&#xa0;h in a 5-L fermentor. Importantly, 4′-O-methylresveratrol exhibited stronger anticancer activity than resveratrol, with significant cytotoxic effects observed against A549 (lung carcinoma) and HepG2 (liver carcinoma) cell lines. To our knowledge, this is the first report demonstrating the anticancer potential of 4′-O-methylresveratrol produced via microbial biosynthesis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Enhanced production of methylated resveratrol in engineered Escherichia coli and its anticancer activity

  • 期刊论文

  • 发表日期：

    2025年8月1日

查看全文
  • Nguyen Quang Huy,
  • Quyen My Linh,
  • Nguyen Thi An Hoa,
  • Do Minh Ha,
  • Tran Van Tuan,
  • Luan Luong Chu

摘要

Resveratrol, a prominent member of the plant-derived stilbenoid family, exhibits diverse biological and pharmaceutical activities. Its methylated derivatives possess enhanced attributes compared to the parent compound, such as improved stability and bioavailability. Although resveratrol analogs are widely used in healthcare and industrial applications, their current production relies predominantly on plant extraction, which often leads to low yields and inconsistent product quality. Microbial biosynthesis offers a promising alternative to chemical synthesis and plant-based extraction. Furthermore, gene expression regulation of engineered microbes allows cells to respond to their environment and maintain proper cellular function, which results in improved target products. In this study, we developed synthetic gene clusters comprising O-methyltransferase from Streptomyces avermitilis (SaOMT2) and S-adenosylmethionine (SAM) synthase from Escherichia coli (E. coli) (EcMetK), resulting in the engineered E. coli biosynthesis of methylated resveratrol. The engineered C2 strain, in which both genes were individually regulated by T7 promoters and ribosome binding site (RBS), demonstrated a 6.1-fold increase in 4′-O-methylresveratrol production compared to the control strain C0 harboring SaOMT2. Optimization of culture conditions, including medium composition and substrate concentration, further enhanced bioconversion efficiency. The bioproductivity of 4′-O-methylresveratrol production was obtained as 476.72 µM (~ 115.485 mg/L) at 36 h in a 5-L fermentor. Importantly, 4′-O-methylresveratrol exhibited stronger anticancer activity than resveratrol, with significant cytotoxic effects observed against A549 (lung carcinoma) and HepG2 (liver carcinoma) cell lines. To our knowledge, this is the first report demonstrating the anticancer potential of 4′-O-methylresveratrol produced via microbial biosynthesis.